Abstract
Preterm delivery represents the major cause of neonatal morbidity and mortality. Respiratory morbidity is the primary cause of early neonatal mortality and disability. The administration of antenatal corticosteroids, in cases of imminent preterm delivery, can enhance fetal lung maturation and reduce the incidence of respiratory distress syndrome, leading to improved neonatal outcomes. The scope of this narrative review was to synthesize available evidence on the efficacy and safety of corticosteroids' administration during antenatal period, in cases of anticipated preterm delivery. Hence, for those cases, a single course of antenatal corticosteroids from 24 up to 34 gestational weeks should be offered. Betamethasone and dexamethasone are the most widely used drugs, with similar effectiveness and a recommended dosage of 24mg in divided doses, over a 24- hour period. However, there is an ongoing debate regarding the gestational age of administration. Some obstetric societies recommend their administration even at 22 weeks of gestation. Conflicting is also their usefulness in late preterm cases (between 34 and 37 weeks) or in cases of elective cesarean delivery at term. The use of repeated courses of corticosteroids may be considered in specific cases, however, concerns on the long-term outcomes of repeated courses beyond 34 gestational weeks have been raised.
Keywords: Corticosteroids, pregnancy, fetal lung maturation, preterm delivery, prematurity, timing, course, outcome.
Current Pharmaceutical Design
Title:Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Volume: 27 Issue: 36
Author(s): Themistoklis Dagklis, Ioannis Tsakiridis, Georgios Papazisis and Apostolos Athanasiadis*
Affiliation:
- Third Department of Obstetrics and Gynaecology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki,Greece
Keywords: Corticosteroids, pregnancy, fetal lung maturation, preterm delivery, prematurity, timing, course, outcome.
Abstract: Preterm delivery represents the major cause of neonatal morbidity and mortality. Respiratory morbidity is the primary cause of early neonatal mortality and disability. The administration of antenatal corticosteroids, in cases of imminent preterm delivery, can enhance fetal lung maturation and reduce the incidence of respiratory distress syndrome, leading to improved neonatal outcomes. The scope of this narrative review was to synthesize available evidence on the efficacy and safety of corticosteroids' administration during antenatal period, in cases of anticipated preterm delivery. Hence, for those cases, a single course of antenatal corticosteroids from 24 up to 34 gestational weeks should be offered. Betamethasone and dexamethasone are the most widely used drugs, with similar effectiveness and a recommended dosage of 24mg in divided doses, over a 24- hour period. However, there is an ongoing debate regarding the gestational age of administration. Some obstetric societies recommend their administration even at 22 weeks of gestation. Conflicting is also their usefulness in late preterm cases (between 34 and 37 weeks) or in cases of elective cesarean delivery at term. The use of repeated courses of corticosteroids may be considered in specific cases, however, concerns on the long-term outcomes of repeated courses beyond 34 gestational weeks have been raised.
Export Options
About this article
Cite this article as:
Dagklis Themistoklis , Tsakiridis Ioannis , Papazisis Georgios and Athanasiadis Apostolos *, Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery, Current Pharmaceutical Design 2021; 27 (36) . https://dx.doi.org/10.2174/1381612826666201207102910
DOI https://dx.doi.org/10.2174/1381612826666201207102910 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure
Current Vascular Pharmacology Skin Tests in the Diagnosis of Drug Hypersensitivity Reactions
Current Pharmaceutical Design Efficacy of Rituximab on Refractory Organ Involvements in Granulomatosis with Polyangiitis: A Systematic Review of Case Reports
Current Rheumatology Reviews Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Deciphering Tuberculous Meningitis: From Clinical Challenges to Novel Models and Pathogenic Pathways
Current Topics in Medicinal Chemistry Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Current Pharmaceutical Design Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Medicinal Plants and Atherosclerosis: A Review on Molecular Aspects
Current Pharmaceutical Design Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents